Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 9, 2020The OncologistOpen Access

The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities

View Full Paper
Ask AI
Bookmark
Share

Authors

LKLaura J. KlesseUniversity of MinnesotaJJJustin T. JordanBoston UniversityHRHeather B. RadtkeTSC Alliance

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Klesse et al. (2020) studied this question.

synapsesocial.com/papers/6a198543f3c200df10587d7ehttps://doi.org/10.1634/theoncologist.2020-0069
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas1997 · 640 citations
  2. 2Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group2012 · 1,342 citations
  3. 3Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma2019 · 1,422 citations
  4. 4Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 12008 · 263 citations
  5. 5A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study2017 · 317 citations